

Ref: STEX/OUTCOME/2023-24

Date: 08.08.2023

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
---	--

Sub. : Outcome of Board Meeting

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023, were approved by the Board of Directors of the Company at its meeting held today at 12.30 P.M. and concluded at 02.15 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023; and
- Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter.

We request you to take the same on record

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2023, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com


Un-audited Standalone and Consolidated Financial Results for the Quarter ended as on 30th June'2023

PART I

Rupees in Lacs (Except per Share Data)

	Particulars	Standalone				Consolidated			
		Three Month period Ended		Year Ended		Three Month period Ended		Year Ended	
		30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited
1	Income from operations								
	(a) Net Sales / Income from operations	4,050.34	3,714.83	3,308.80	13,788.40	4,194.31	3,866.54	3,308.80	14,086.74
	(b) Other Income	37.92	34.65	96.23	246.22	37.92	34.65	96.23	246.22
	(c) Total Revenue	4,088.26	3,749.48	3,405.03	14,034.62	4,232.23	3,901.19	3,405.03	14,332.96
2	Expenses								
	a) Cost of Material Consumed	2,581.84	2,247.98	1,690.39	8,180.29	2,610.85	2,215.94	1,690.39	8,180.29
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(524.06)	(109.86)	(0.93)	(1,029.82)	(524.14)	(50.99)	(0.93)	(970.95)
	d) Employees Benefits Expenses	524.65	437.94	434.18	1,856.88	656.39	551.93	434.18	2,044.38
	e) Finance Cost	95.65	85.76	76.72	292.27	95.65	85.76	76.72	292.27
	f) Depreciation and Amortisation Expenses	167.97	160.97	152.72	635.35	169.08	162.28	152.72	636.66
	g) Other expenses	726.88	462.00	619.45	2,366.38	756.07	500.73	619.45	2,445.82
	Total Expenses	3,572.93	3,284.79	2,972.53	12,301.34	3,763.90	3,465.64	2,972.53	12,628.46
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	515.33	464.70	432.50	1,733.28	468.33	435.55	432.50	1,704.50
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	515.33	464.70	432.50	1,733.28	468.33	435.55	432.50	1,704.50
6	Tax Expenses								
	Current Year	124.62	107.50	97.88	369.96	124.62	107.51	97.88	369.96
	MAT Credit Entitlement	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(50.99)	(47.40)	(23.93)	(136.88)	(50.99)	(48.83)	(23.93)	(138.31)
	Total Tax Expense	73.63	60.10	73.94	233.08	73.63	58.68	73.94	231.65
7	Net Profit /Loss for the period from Continuing operation (5- 6)	441.70	404.60	358.56	1,500.20	394.70	376.87	358.56	1,472.85

R. B. Bhatnagar



8	Other Comprehensive Income								
	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	441.70	404.60	358.56	1,500.20	394.70	376.87	358.56	1,472.85
10	Net Profit /Loss attributable to								
	a) Controlling Interest					417.72	388.97	358.56	1,484.41
	b) Non-controlling Interest					(23.02)	(12.10)	-	(11.56)
10	Paid up equity share capital								
	(Rs. 10/- per share)	1,265.11	1,265.11	1,221.66	1,265.11	1,265.11	1,265.11	1,221.66	1,265.11
11	Earning Per Share (Rs.)								
	Basic	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82
	Diluted	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82

NOTES :

- 1 The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8 August 2023
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- 5 The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- 6 Limited review report has been carried out by the Statutory Auditors for the above period.
- 7 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi

Dated : 08.08.2023

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS




Independent Auditor's Limited Review Report on unaudited standalone financial results of Medicamen Biotech Limited for the quarter ended June 30, 2023, pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of
Medicamen Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medicamen Biotech Limited ('the Company') for the quarter ended June 30, 2023 ('the Statement') attached herewith, being prepared and submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant Rules issued thereunder and other accounting principles generally accepted in India, read with the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in all material respects in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder including the amendments thereof and other recognized accounting practices and policies generally accepted in India, has ~~not~~ disclosed the information required to be disclosed in accordance with the requirements of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants


Qimat Rai Garg
Partner

(Membership Number: 080857)

UDIN: 23080857BGYGVG8980

Place: Gurugram

Date: 08.08.2023



Independent Auditor's limited review report on unaudited consolidated financial results of Medicamen Biotech Limited for the quarter ended June 30, 2023 pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of
Medicamen Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Medicamen Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023 (the 'Statement') attached herewith, being prepared and submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended thereafter ('the Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial results of the following entities:

Subsidiaries

Opal Pharmaceutical Pty Ltd
Medicamen Life Sciences Private Limited


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principle laid down in the aforesaid Indian Accounting Standard ('Ind AS') prescribed under Section 133 the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to

be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects total revenue of Rs. 143.97 and, total net (loss) after tax of Rs. 0.47 lakhs and total comprehensive loss of Rs. 0.47 lakhs for the quarter ended June 30, 2023 as considered in the Statement. This interim financial information have been furnished to us by the management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion on the statement is not modified in respect of matter stated in paragraph above.

For Rai Qimat & Associates
Chartered Accountants


Qimat Rai Garg
Partner

(Membership Number: 080857)

UDIN: 23080857BGYGVH9681

Place: Gurugram

Date: 08.08.2023